Pharmaceutical Analysis, Department of Organic Chemistry, School of Pharmaceutical and Biochemical Sciences, National University of Rosario and Institute of Chemistry of Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario, S2002LRK, Argentina.
Pharmaceutical Analysis, Department of Organic Chemistry, School of Pharmaceutical and Biochemical Sciences, National University of Rosario and Institute of Chemistry of Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario, S2002LRK, Argentina.
Eur J Pharm Sci. 2020 Apr 15;146:105267. doi: 10.1016/j.ejps.2020.105267. Epub 2020 Feb 13.
Praziquantel (PZQ) is a highly effective low-cost anthelmintic agent used as the first-choice treatment against schistosomiasis. The low solubility of the active is a major drawback for pharmaceutical formulation. A valid approach of the pharmaceutical industry for the improvement of the pharmacotechnical features of the active principles (such as solubility, processability, stability, among others), is the preparation of new solid forms, such as salts, polymorph, and pseudo-polymorph. Herein we report the preparation and characterization of a new solid form PZQ. The PZQ monohydrate (PZQ-MH) was prepared by a solventless procedure from the commercial racemate and the product was characterized at the solid-state employing optical digital microscopy, thermal methods (melting point, differential scanning calorimetry and thermogravimetric analysis), as well as and mid-infrared and near infrared spectroscopies. The chemical structure and content of water were full assessed by H nuclear magnetic resonance (NMR) in solution. The amount of water in PZQ-was also determined by different approaches, including thermogravimetric analysis and the loss on drying test. Solid-state C NMR (ssNMR) and X-ray powder diffraction (XRPD) completed the structural characterization of the new monohydrate. PZQ-MH showed a crystalline behavior during XRPD experiments and showed relevant differences in spectroscopic, calorimetric, ssNMR and XRPD signals when it was compared with the known crystal (Form A) and amorphous forms of PZQ. The determination of the intrinsic dissolution rate (IDR) of PZQ-MH was carried out as a functional characterization, observing that the new form had slightly higher IDR than Form A.
吡喹酮(PZQ)是一种高效、低成本的驱肠虫药,是治疗血吸虫病的首选药物。其活性成分溶解度低是药物制剂的主要缺点。制药行业提高活性药物(如溶解度、可加工性、稳定性等)的制药技术特性的有效方法是制备新的固体形式,如盐、多晶型和假多晶型。本文报道了一种新的吡喹酮固体形式的制备和表征。吡喹酮一水合物(PZQ-MH)是由商业外消旋体制备的,采用无溶剂法制备,产物在固态下采用光学数字显微镜、热法(熔点、差示扫描量热法和热重分析)以及中红外和近红外光谱进行了表征。通过溶液中的 H 核磁共振(NMR)充分评估了化学结构和水的含量。通过热重分析和干燥失重试验等不同方法也确定了 PZQ 中的含水量。固态 C 核磁共振(ssNMR)和 X 射线粉末衍射(XRPD)完成了新一水合物的结构表征。PZQ-MH 在 XRPD 实验中表现出结晶行为,与已知的晶体(A 型)和无定形 PZQ 相比,在光谱、热分析、ssNMR 和 XRPD 信号方面表现出明显差异。还进行了 PZQ-MH 的固有溶出速率(IDR)的测定作为功能表征,观察到新形式的 IDR 略高于 A 型。